Skip to main content
. 2023 Oct 30;55:101188. doi: 10.1016/j.nmni.2023.101188

Table 2.

Multivariable model of COVID-19 mortality among patients treated in our center 2020–2021 (n ​= ​30,202a).

Model A
 p Model B
OR 95% CIb p aOR, 95% CIc OR, 95% CI‡ P aOR, 95% CIc P
Sex (ref. Women) Men 1.61 1.32–1.96 <.001 1.61 1.32–1.96 <.001
Age (Ref. <50) 50–69 6.52 3.21–13.3 <.001 6.47 3.19–13.1 <.001
70–89 40.4 20.2–80.7 <.001 39.4 19.7–78.6 <.001
>89 89.9 43.0–188 <.001 86.4 41.4–180 <.001
Period (Ref. 2020/03/03-2–020/06/15) 2020/06/16-2–020/09/20 0.94 0.61–1.46 0.787 0.92 0.59–1.43 .704
2020/09/21-2–020/11/22 1.21 0.83–1.76 0.313 1.16 0.80–1.69 .438
2020/11/23-2–021/03/21 1.96 1.39–2.77 <.001 1.90 1.34–2.68 <.001
2021/03/22-2–021/06/27 1.06 0.71–1.58 0.787 0.99 0.65–1.50 .958
2021/06/28-2–021/09/21 1.13 0.72–1.76 0.599 1.06 0.67–1.69 .789
2021/09/22-2–021/12/31 1.27 0.83–1.95 0.262 1.22 0.78–1.91 .395
Outpatients (ref. No) Yes 0.05 0.04–0.07 <.001 0.05 0.04–0.07 <.001
Treatment (ref. HCQ-AZd (n ​= ​23,172)) HCQ-AZ vs. No HCQ-AZd (n ​= ​7,030) 0.16 0.14–0.19 <.001 0.55 0.45–0.68 <.001 HCQ-AZ vs. AZ-onlyd (n ​= ​3144) 0.10 0.07–0.13 <.001 0.51 0.35–0.72 <.001
HCQ-AZ vs. IVM-AZd (n ​= ​1434) 0.17 0.11–0.27 <.001 0.54 0.31–0.97 .029
HCQ-AZ vs. HCQ-onlyd (n ​= ​566) 0.67 0.20–2.26 .974 0.85 0.22–3.25 1.000
HCQ-AZ vs. IVM-AZ-delayed HCQd (n ​= ​329) 0.15 0.07–0.33 <.001 0.44 0.17–1.15 .157
HCQ-AZ vs. IVM-onlyd (n ​= ​98) 0.07 0.03–0.21 <.001 0.50 0.15–1.72 .692
HCQ-AZ vs. HCQ-IVMd (n ​= ​17) 0.27 0.00–23.9 .988 0.93 0.00–178 1.000
HCQ-AZ vs. Other treatment (n ​= ​1771) 0.37 0.21–0.64 <.001 0.49 0.26–0.93 .018

Tukey's correction was used to calculate P values and odds ratios for the treatment group variables (model B).

a

A total of 221 patients were excluded due to missing treatment data (see Table 1).

b

Crude odds ratio with 95% confidence interval.

c

Adjusted odds ratio with 95% confidence interval.

d

HCQ: Hydroxychloroquine, AZ: Azithromycin, IVM: Ivermectin.